Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Director | March 21, 2024 | March 25, 2024 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date March 21, 2024 · Filed March 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,703 |
Ending reported balance
After 2024-03-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-21 · Exercise / conversion · Acquired 23,491 · Balance 54,908 Row 2 · 2024-03-21 · Sale · Disposed 19,205 · Balance 35,703 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 8, 2023. F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.57 · Expires 2024-05-24 | Direct | 0 |
Reported balance
After 2024-03-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-21 · Exercise / conversion · Disposed 23,491 · Balance 0 F3: The option, representing the right to purchase a total of 23,491 shares of Exelixis, Inc. common stock became fully exercisable on May 25, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 8, 2023.
F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3: The option, representing the right to purchase a total of 23,491 shares of Exelixis, Inc. common stock became fully exercisable on May 25, 2017.
VERTEX PHARMACEUTICALS INC / MA
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 65.458 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 31.56 · Balance 65.458 F1: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 31.56 | $475.28 | $14,999.84 |
DisclosureSEC source: 0000875320-26-000247 · wk-form4_1784318742.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65.458 Underlying: Common Stock · 31.56 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 1,433 | $0.00 Strike: $424.45 | $0.00 |
DisclosureSEC source: 0000875320-26-000179 · wk-form4_1778014724.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,433 Underlying: Common Stock · 1,433 shares Expires 2036-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 472 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000179 · wk-form4_1778014724.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,344 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantDeferred Stock Units · Derivative | 33.898 | $442.50 | $14,999.87 |
DisclosureSEC source: 0000875320-26-000159 · wk-form4_1776456893.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33.898 Underlying: Common Stock · 33.898 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 1,199 | $0.00 Strike: $502.97 | $0.00 |
DisclosureSEC source: 0000875320-25-000177 · wk-form4_1746476345.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,199 Underlying: Common Stock · 1,199 shares Expires 2035-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 398 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000177 · wk-form4_1746476345.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,872 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,142 | $0.00 Strike: $399.71 | $0.00 |
DisclosureSEC source: 0000875320-24-000121 · wk-form4_1714767073.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,142 Underlying: Common Stock · 3,142 shares Expires 2034-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 23:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 23,491 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-24-000036 · wk-form4_1711409469.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,491 shares Expires 2024-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 23,491 shares of Exelixis, Inc. common stock became fully exercisable on May 25, 2017. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 23:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 19,205 | $24.01 | $461,112.05 |
DisclosureSEC source: 0000939767-24-000036 · wk-form4_1711409469.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,703 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 8, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 23:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 23,491 | $19.57 | $459,718.87 |
DisclosureSEC source: 0000939767-24-000036 · wk-form4_1711409469.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2023 Filed Jun 3, 2023 01:24 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 44,087 | $0.00 Strike: $19.39 | $0.00 |
DisclosureSEC source: 0000939767-23-000062 · wk-form4_1685755448.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,087 Underlying: Common Stock · 44,087 shares Expires 2030-05-31 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 1,741 | $0.00 Strike: $342.73 | $0.00 |
DisclosureSEC source: 0001209191-23-027015 · doc4.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,741 Underlying: Common Stock · 1,741 shares Expires 2033-04-30 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 584 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027015 · doc4.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,474 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000939767-23-000028 · wf-form4_167720447178170.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $17.49 | $699,600.00 |
DisclosureSEC source: 0000939767-23-000028 · wf-form4_167720447178170.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,417 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 2, 2022. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.55. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $6.30 | $252,000.00 |
DisclosureSEC source: 0000939767-23-000028 · wf-form4_167720447178170.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 28, 2022 00:15 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 42,422 | $0.00 Strike: $18.19 | $0.00 |
DisclosureSEC source: 0000939767-22-000073 · wf-form4_165369690559101.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,422 Underlying: Common Stock · 42,422 shares Expires 2029-05-25 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 4,462 | $0.00 Strike: $276.17 | $0.00 |
DisclosureSEC source: 0000899243-22-016329 · doc4.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,462 Underlying: Common Stock · 4,462 shares Expires 2032-04-30 Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0000939767-22-000034 · wf-form4_164635603258608.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2022-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 21,301 | $21.00 | $447,321.00 |
DisclosureSEC source: 0000939767-22-000034 · wf-form4_164635603258608.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,417 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2021. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $3.13 | $125,200.00 |
DisclosureSEC source: 0000939767-22-000034 · wf-form4_164635603258608.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2021 Filed May 29, 2021 00:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 33,549 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0000939767-21-000060 · wf-form4_162224738849446.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,549 Underlying: Common Stock · 33,549 shares Expires 2028-05-26 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 6,067 | $0.00 Strike: $217.20 | $0.00 |
DisclosureSEC source: 0001209191-21-029845 · doc4.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,067 Underlying: Common Stock · 6,067 shares Expires 2031-04-30 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000939767-21-000037 · wf-form4_161602625006192.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2021-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $23.60 | $944,000.00 |
DisclosureSEC source: 0000939767-21-000037 · wf-form4_161602625006192.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,718 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2020. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.09 to $23.74. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $3.38 | $135,200.00 |
DisclosureSEC source: 0000939767-21-000037 · wf-form4_161602625006192.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 2,264 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034012 · doc4.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,264 Underlying: Common Stock · 2,264 shares Expires 2030-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 699 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034012 · doc4.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,890 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 22, 2020 Filed May 23, 2020 00:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 36,111 | $24.42 | $881,830.62 |
DisclosureSEC source: 0000939767-20-000091 · wf-form4_159019520279217.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,718 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.22 to $24.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| May 21, 2020 Filed May 23, 2020 00:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 30,750 | $0.00 Strike: $24.62 | $0.00 |
DisclosureSEC source: 0000939767-20-000091 · wf-form4_159019520279217.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,750 Underlying: Common Stock · 30,750 shares Expires 2027-05-20 F3 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| February 14, 2020 Filed Feb 15, 2020 01:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 12,500 | $21.02 | $262,750.00 |
DisclosureSEC source: 0000939767-20-000016 · wf-form4_158173056798179.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,829 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.03. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 01:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 56,956 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0000939767-20-000003 · wf-form4_157861988780844.xml · derivative · entry 5 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,956 shares Expires 2020-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: The option, representing the right to purchase a total of 56,956 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 01:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000939767-20-000003 · wf-form4_157861988780844.xml · derivative · entry 4 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 01:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 86,956 | $18.01 | $1,566,077.56 |
DisclosureSEC source: 0000939767-20-000003 · wf-form4_157861988780844.xml · nonDerivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 01:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 56,956 | $5.82 | $331,483.92 |
DisclosureSEC source: 0000939767-20-000003 · wf-form4_157861988780844.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 01:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $4.58 | $137,400.00 |
DisclosureSEC source: 0000939767-20-000003 · wf-form4_157861988780844.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,330 | $0.00 Strike: $168.04 | $0.00 |
DisclosureSEC source: 0001209191-19-034223 · doc4.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,330 Underlying: Common Stock · 3,330 shares Expires 2029-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-034223 · doc4.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,191 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000135 · wf-form4_155874509766298.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · derivative · entry 6 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · derivative · entry 5 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-05-18 F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $23.97 | $359,550.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 4 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2018 and modified on February 28, 2019. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.89 to $24.14. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $24.00 | $360,000.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2018 and modified on February 28, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $5.92 | $88,800.00 |
DisclosureSEC source: 0000939767-19-000078 · wf-form4_155433591000438.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 00:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-19-000009 · wf-form4_154708125252237.xml · derivative · entry 3 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2010. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 00:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 11,250 | $23.00 | $258,750.00 |
DisclosureSEC source: 0000939767-19-000009 · wf-form4_154708125252237.xml · nonDerivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,329 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2018. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 00:47 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-19-000009 · wf-form4_154708125252237.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 3,229 | $0.00 Strike: $152.74 | $0.00 |
DisclosureSEC source: 0001209191-18-035796 · doc4.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,229 Underlying: Common Stock · 3,229 shares Expires 2028-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035796 · doc4.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.